Impact of estradiol valerate/dienogest on work productivity and activities of
daily living in women with heavy menstrual bleeding.
Author(s): Wasiak R(1), Filonenko A, Vanness DJ, Law A, Jeddi M, Wittrup-Jensen KU, Stull
DE, Siak S, Jensen JT.
Affiliation(s): Author information:
(1)United BioSource Corporation, London, United Kingdom.
Publication date & source: 2013, J Womens Health (Larchmt). , 22(4):378-84
OBJECTIVES: To quantify the change in work productivity and activities of daily
living in North American women with heavy menstrual bleeding (HMB) treated with
estradiol valerate/dienogest (E2V/DNG; Qlaira(®)/Natazia(®)) compared to placebo.
METHODS: Women in the United States and Canada, aged 20-53 years with an
objective diagnosis of HMB and no recognizable anatomical pathology, were treated
with E2V/DNG or placebo for seven cycles (196 days). Main outcome measures
included work productivity (i.e., productivity while at work) and activities of
daily living measured using a modified Work Productivity and Activity Impairment
Questionnaire (mWPAI) on a Likert scale from 0 to 10 (higher values denote higher
impairment levels).
RESULTS: In both countries, significant improvement was observed between baseline
and end of treatment in work productivity and activities of daily living
impairment. The improvements in work productivity and activities of daily living
with E2V/DNG treatment relative to placebo ranged from 37.2% to 39.2% across both
countries. Monthly gains due to E2V/DNG treatment (net of placebo improvement)
associated with improvement in work productivity were estimated to be US$80.2 and
Can$70.8 (US$58.5) and those associated with improvement in activities of daily
living were estimated to be US$84.9 and Can$73.5 (US$60.7).
CONCLUSIONS: E2V/DNG was shown to have a consistent positive impact on work
productivity and activities of daily living in U.S. and Canadian women with HMB.
In addition, these improvements in work productivity and activities of daily
living were associated with a reduction in HMB-related monetary burden compared
to the placebo group.
|